H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data “raises questions over its viability.” As such, the firm removed risk-adjusted revenue forecasts for the agent.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX: